Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

CEO Tal Zaks shares Exsilio’s origin story and the exciting science that convinced him to helm the nascent biotech.

Exsilio Therapeutics CEO and OrbiMed partner Tal Zaks on how he shows investors the value path for cutting-edge research.

Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

Since 2008, PCM Trials has led the way in mobile research. Our Certified Mobile Research Nurses (CMRNs) are driving the shift to patient-centric, decentralized clinical trials, giving individuals the ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Revolo Biotherapeutics’ pipeline is focusing on creating a commercially viable subcutaneous dosage form for its lead candidate while working on a sublingual solution that is even more patient friendly ...

In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for ...

Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) ...

Aron Knickerbocker leverages his Big Pharma credentials to launch successful biotech startups, including his most recent venture, Aulos, which uses AI to accelerate drug development.